Lilly's Trulicity (Dulaglutide) Now Available in US Pharmacies

The newest GLP-1 receptor agonist treatment option to help improve glycemic control type 2 diabetes in adults is now available in US pharmacies. Eli Lilly and Company's Trulicity (dulaglutide) is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed with patients in mind. It comes in a single-dose pen and does not require the patient to mix, measure or handle the needle.

"Some adults with type 2 diabetes find that diet, exercise and oral medicines aren't enough to meet their treatment goals," said Dr Laura Fernandez, senior medical advisor, Lilly Diabetes. "Trulicity may be an option for them as it has demonstrated proven glycemic control, only has to be taken once weekly, and comes in an easy-to-use pen."

Trulicity is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Trulicity is not recommended as first-line therapy for patients inadequately controlled on diet and exercise. It has not been studied in patients with a history of pancreatitis, and other antidiabetic therapies should be considered for patients with a history of pancreatitis. Trulicity is not for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. Trulicity is not a substitute for insulin and has not been studied in combination with basal insulin. Trulicity has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is not for patients with pre-existing severe gastrointestinal disease.